Cargando…
Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261131/ https://www.ncbi.nlm.nih.gov/pubmed/35818395 http://dx.doi.org/10.1186/s40537-022-00641-z |
_version_ | 1784742205695459328 |
---|---|
author | Gui, Cheng-Peng Li, Jia-Ying Fu, Liang-Min Luo, Cheng-Gong Zhang, Chi Tang, Yi-Ming Zhang, Li-zhen Shu, Guan-nan Wu, Rong-Pei Luo, Jun-Hang |
author_facet | Gui, Cheng-Peng Li, Jia-Ying Fu, Liang-Min Luo, Cheng-Gong Zhang, Chi Tang, Yi-Ming Zhang, Li-zhen Shu, Guan-nan Wu, Rong-Pei Luo, Jun-Hang |
author_sort | Gui, Cheng-Peng |
collection | PubMed |
description | BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patients were extracted from TCGA-BLCA, three GEO databases and IMvigor210 cohort. We comprehensively established the FeME landscape of 1216 BCa samples based on 290 ferroptosis related genes (FRGs), and systematically correlated these regulation patterns with TME cell-infiltrating characteristics. Besides, we identified the patients’ ferroptosis risk index (FRI) to predict the prognosis of BCa for precise treatment. RESULTS: Six over-expressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in BCa. Furthermore, we demonstrated the evaluation of FeME within individual tumors could predict stages of tumor inflammation, subtypes, genetic variation, and patient prognosis. Then, 5-lncRNA signature was mined to produce the FRI. Low FRI was also linked to increased mutation load, better prognosis and enhanced response to anti-PD-L1 immunotherapy. Besides, an immunotherapy cohort confirmed patients with lower FRI demonstrated significant therapeutic advantages and clinical benefits. CONCLUSIONS: TFRC, SCD, G6PD, FADS2, SQLE, and SLC3A2 are potent antigens for developing anti-BCa mRNA vaccine. Establishment of FRI will contribute to enhancing our cognition of TME infiltration characterization and guiding more effective immunotherapy strategies and selecting appropriate patients for tumor vaccine therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40537-022-00641-z. |
format | Online Article Text |
id | pubmed-9261131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92611312022-07-07 Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer Gui, Cheng-Peng Li, Jia-Ying Fu, Liang-Min Luo, Cheng-Gong Zhang, Chi Tang, Yi-Ming Zhang, Li-zhen Shu, Guan-nan Wu, Rong-Pei Luo, Jun-Hang J Big Data Research BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patients were extracted from TCGA-BLCA, three GEO databases and IMvigor210 cohort. We comprehensively established the FeME landscape of 1216 BCa samples based on 290 ferroptosis related genes (FRGs), and systematically correlated these regulation patterns with TME cell-infiltrating characteristics. Besides, we identified the patients’ ferroptosis risk index (FRI) to predict the prognosis of BCa for precise treatment. RESULTS: Six over-expressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in BCa. Furthermore, we demonstrated the evaluation of FeME within individual tumors could predict stages of tumor inflammation, subtypes, genetic variation, and patient prognosis. Then, 5-lncRNA signature was mined to produce the FRI. Low FRI was also linked to increased mutation load, better prognosis and enhanced response to anti-PD-L1 immunotherapy. Besides, an immunotherapy cohort confirmed patients with lower FRI demonstrated significant therapeutic advantages and clinical benefits. CONCLUSIONS: TFRC, SCD, G6PD, FADS2, SQLE, and SLC3A2 are potent antigens for developing anti-BCa mRNA vaccine. Establishment of FRI will contribute to enhancing our cognition of TME infiltration characterization and guiding more effective immunotherapy strategies and selecting appropriate patients for tumor vaccine therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40537-022-00641-z. Springer International Publishing 2022-07-07 2022 /pmc/articles/PMC9261131/ /pubmed/35818395 http://dx.doi.org/10.1186/s40537-022-00641-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Gui, Cheng-Peng Li, Jia-Ying Fu, Liang-Min Luo, Cheng-Gong Zhang, Chi Tang, Yi-Ming Zhang, Li-zhen Shu, Guan-nan Wu, Rong-Pei Luo, Jun-Hang Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title | Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title_full | Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title_fullStr | Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title_full_unstemmed | Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title_short | Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
title_sort | identification of mrna vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261131/ https://www.ncbi.nlm.nih.gov/pubmed/35818395 http://dx.doi.org/10.1186/s40537-022-00641-z |
work_keys_str_mv | AT guichengpeng identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT lijiaying identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT fuliangmin identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT luochenggong identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT zhangchi identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT tangyiming identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT zhanglizhen identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT shuguannan identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT wurongpei identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer AT luojunhang identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer |